Tebipenem pivoxil hydrobromide is a Small Molecule owned by Meiji Seika Pharma, and is involved in 16 clinical trials, of which 12 were completed, 2 are ongoing, and 2 are planned.

Orapenem (SPR-994) acts by inhibiting the activity of penicillin binding protein, a bacterial cell wall synthase, and thereby inhibiting cell wall synthesis. Tebipenem has high affinity for multiple PBPs of Streptococcus pneumoniae and Haemophilus influenzae, and is less susceptible to the accumulation of amino acid substitutions, so it has strong antibacterial activity against resistant bacteria.

The revenue for Tebipenem pivoxil hydrobromide is expected to reach a total of $3.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tebipenem pivoxil hydrobromide NPV Report.

Tebipenem pivoxil hydrobromide is currently owned by Meiji Seika Pharma. Spero Therapeutics is the other company associated in development or marketing of Tebipenem pivoxil hydrobromide.

Tebipenem pivoxil hydrobromide Overview

Tebipenem pivoxil hydrobromide (Orapenem) belongs to the class of carbapenem antibiotic. The drug is formulated as granules for oral route of administration and it is used for the treatment of pneumonia, otitis media, and nasal inflammation.

SPR-994 was under development for the treatment of multi-drug resistant gram-negative bacterial urinary tract infections caused by Escherichia coli, Klebsiella pneumonia and community-acquired bacterial pneumonia and acute pyelonephritis. It is formulated as an immediate release tablet and administered through the oral route. The drug candidate acts by targeting extended-spectrum beta-lactamase (ESBL) enzymes. It was under development for gram-positive bacteria, diabetic foot infections.

Spero Therapeutics Overview

Spero Therapeutics. (Spero) is a clinical-stage biopharmaceutical company. It is engaged in developing, identifying and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Its product pipeline includes SPR994 oral gram-negative program, SPR741and SPR206 IV potentiator platform, and SPR720 non-tuberculosis mycobacterium. The company markets its products through third party distributors. Its partners include U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Defense (DoD) and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Spero is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$18.3 million for the fiscal year ended December 2021 (FY2021), an increase of 95.7% over FY2020. The operating loss of the company was US$88 million in FY2021, compared to an operating loss of US$79.1 million in FY2020. The net loss of the company was US$89.8 million in FY2021, compared to a net loss of US$78.3 million in FY2020. The company reported revenues of US$2 million for the third quarter ended September 2022, an increase of 0.7% over the previous quarter.

Quick View – Tebipenem pivoxil hydrobromide

Report Segments
  • Innovator (NME)
Drug Name
  • Tebipenem pivoxil hydrobromide
Administration Pathway
  • Oral
Therapeutic Areas
  • Ear Nose Throat Disorders
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.